Showing 4711-4720 of 4940 results for "".
- ASDS Election Results Announcedhttps://practicaldermatology.com/news/20121023-asds_election_results_announced/2459696/The ASDS has elected new officers and members of its Board of Directors whose terms began at the recent annual meeting in Atlanta. Dr. George Hruza, Clinical Professor of Dermatology and Otolaryngology at St. Louis University, was elected Vice President and will ascend to President-Elect in 2013-14
- STELARA Wins 2012 International Prix Galien Awardhttps://practicaldermatology.com/news/20121022-stelara_wins_2012_international_prix_galien_award/2459698/Janssen Biotech, Inc. announced that STELARA was named the 2012 International Prix Galien award winner in Lyon, France. The honor is acknowledgment of the technical, scientific, and clinical research skills necessary to develop innovative medicines and devices. The international Prix Galien Award is
- Nuvo and Galderma Win FDA Approval for Topical Peelhttps://practicaldermatology.com/news/20121022-nuvo_and_galderma_win_fda_approval_for_topical_peel/2459699/Nuvo Research announced that the FDA has approved its Pliaglis product, a topical anesthetic cream designed to minimize pain during aesthetic dermatological procedures such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal. The approval
- Sanofi, Coca-Cola Begin Drink Projecthttps://practicaldermatology.com/news/20121018-sanofi_coca-cola_begin_drink_project/2459700/Sanofi and Coca-Cola are collaborating on a line of drinks, called Beautific Oenobiol, that will claim to offer improved skin, stronger hair, and increased vitality. The collaboration will begin with four products made with mineral water, fruit juice, and nutritional ingredients to be sold in French
- AMA Releases National EHR Survey for Physician Inputhttps://practicaldermatology.com/news/20121012-ama_releases_national_ehr_survey_for_physician_input/2459708/The American Medical Association (AMA) electronically invited member physicians to share their insights and opinions on the latest electronic health record (EHR) technology through a joint survey with AmericanEHR Partners. Findings are intended to support physicians in the selection, use, and value
- ADCS Clinics Acquires Additional Practicehttps://practicaldermatology.com/news/20121010-adcs_clinics_acquires_additional_practice/2459710/Less than a week after announcing a major acquisition of multiple clinics on Florida's West Coast, Advanced Dermatology & Cosmetic Surgery (ADCS) announced the acquisition of Winter Park Dermatology. The practice is located in Wint
- Celgene to Present Data From Abraxane Melanoma Studyhttps://practicaldermatology.com/news/20121009-celgene_to_present_data_from_abraxane_melanoma_study/2459712/Results from a late-stage clinical trial by Celgene Corp. show its cancer drug Abraxane slows the progression of melanoma. The trial compared Abraxane and dacarbazine in 529 patients with melanoma that had metastasized. The company says that patients treated with Abraxane had greater progression-fre
- Jurlique Offers Holiday Discountshttps://practicaldermatology.com/news/20121002-jurlique_offers_holiday_discounts/2459718/Jurlique released holiday gift sets featuring full-sized product at a 30 to 40 percent savings. The products include: Age-Defying Trio, of Jurlique Purely Age-Defying Serum, Purely Age-Defying Ultra Firm and Lift Cream, and Skin Balancing Face Oi
- Strathspey Crown Hosts Founders Summithttps://practicaldermatology.com/news/20121002-strathspey_crown_hosts_founders_summit/2459717/Strathspey Crown recently hosted its Founders Summit & Retreat at Pelican Hill in Newport Beach, CA. The event gathered approximately 50 of the top physicians from elective healthcare and national leaders from government, healthcare, and f
- Janssen to Develop, Commercialize JAK Inhibitor For Immunological Diseaseshttps://practicaldermatology.com/news/20121002-janssen_to_develop_commercialize_jak_inhibitor_for_immunological_diseases/2459720/Janssen Biotech, Inc. entered into a license agreement with Astellas Pharma Inc. for the worldwide development and commercialization, except in Japan, of ASP015K, an oral, small molecule Janus Kinase (JAK) inhibitor. ASP015K is currently in Phase 2b development as a once-daily oral treatment for mod